Incorporating Future Costs in Medical Cost-Effectiveness Analysis
- 1 October 1997
- journal article
- other
- Published by SAGE Publications in Medical Decision Making
- Vol. 17 (4), 382-389
- https://doi.org/10.1177/0272989x9701700403
Abstract
It has been shown that the difference between consumption and production during life years gained should be included as a cost in cost-effectiveness analysis. In this study the authors estimate the impact of including these future costs on the cost-effective ness of the treatment of hypertension in Sweden. The cost per quality-adjusted life year (QALY) gained changes little among young men and women due to the addition of future costs, but increases by about $14,000 for middle-aged men and women and about $27,000 for older men and women. When future costs are not included, the cost per QALY gained is generally lowest among older men and women, but when future costs are included, the cost per QALY gained is generally lowest among middle-aged men and women. The authors conclude that the total resource consequences of changes in mortality should be routinely considered in cost-effectiveness analyses. Key words: Cost-effectiveness analysis; economic evaluation; costs; societal per spective. (Med Decis Making 1997;17:382-389)Keywords
This publication has 30 references indexed in Scilit:
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- The Cost Effectiveness of Hypertension Treatment in SwedenPharmacoEconomics, 1995
- Discounting health care: only a matter of timing?The Lancet, 1992
- Cost-effectiveness analysis of hypertension treatment — A review of methodological issuesHealth Policy, 1991
- EuroQol©: health-related quality of life measurement. Results of the Swedish questionnaire exerciseHealth Policy, 1991
- An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reductionThe American Journal of Cardiology, 1991
- On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit AnalysesInternational Journal of Technology Assessment in Health Care, 1991
- Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasThe Lancet, 1990
- Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol.BMJ, 1987
- The Economic Costs of Stroke in MassachusettsNew England Journal of Medicine, 1978